Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

French National Institute of Health and Medical Research

Headquarters: Paris, France
Year Founded: 1964
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Mar 31, 2020
Product Development

FDA’s authorization of malaria drugs for COVID-19 looks like political science

Editor’s Commentary: Why FDA's authorization of hydroxychloroquine and chloroquine for COVID-19 is bad for patients
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

How academics connect with industry to build companies
BioCentury | Apr 24, 2018
Distillery Therapeutics

Cardiovascular

BioCentury | Mar 27, 2018
Distillery Therapeutics

Cancer

BioCentury | May 8, 2017
Distillery Therapeutics

Endocrine / Metabolic

BioCentury | Oct 20, 2016
Distillery Techniques

Biomarkers

BioCentury | Aug 3, 2015
Company News

AstraZeneca, INSERM deal

BioCentury | May 12, 2014
Emerging Company Profile

Inotrem: Sepsis companion

Inotrem banking on companion Dx to target TREM1 inhibitors in sepsis
BioCentury | Apr 15, 2014
Financial News

Gene therapy play AAVLife secures $12 million

BioCentury | Mar 24, 2014
Finance

Modulating sepsis

Rationale for investing EUR 18 million in preclinical sepsis play Inotrem
Items per page:
1 - 10 of 39